Indication
ESCC
5 clinical trials
4 products
3 drugs
Product
JAB-8263Clinical trial
A Phase I/IIa, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-8263 in Adult Patients With Advanced Malignant TumorsStatus: Recruiting, Estimated PCD: 2024-01-01
Product
ASP0739Clinical trial
A Phase 1/2 Open-label Study Investigating the Safety, Tolerability and Efficacy of ASP0739 as a Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Known to Express NY-ESO-1Status: Completed, Estimated PCD: 2023-06-01
Product
PembrolizumabClinical trial
An Exploratory Study of the Efficacy and Safety of DCF Regimen Combined With Camrelizumab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma(ESCC)Status: Recruiting, Estimated PCD: 2023-12-01
Drug
PD-1 antibodyDrug
DCFClinical trial
Immunotherapy Combined With Chemoradiotherapy for First-line Treatment of Esophageal Squamous Cell Carcinoma:a Real-world Study From ChinaStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Drug
UTD1Clinical trial
Ivonescimab(AK112) Combined With Chemotherapy as the First-line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma (ESCC): A Single Arm , Phase II TrialStatus: Not yet recruiting, Estimated PCD: 2024-08-30
Product
Ivonescimab